# Anti-Fungal Drugs Market

> Anti-Fungal Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Nicotinamides), By Formulation Type (Injectable, Oral, Topical, Intravaginal), By Treatment Type (Prophylactic Treatment, Therapeutic Treatment), By Patient Type (Pediatric, Adult, Geriatric), By Conditions Treated (Skin Infections, Systemic Infections, Oral Candidiasis, Nail Infections) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 4.15%
- **2025:** USD 18.30 Billion
- **2035:** USD 27.41 Billion
- **Key Players:** Pfizer Inc., Merck & Co., Inc., Astellas Pharma Inc., Gilead Sciences, Inc., Basilea Pharmaceutica, Melinta Therapeutics, Cidara Therapeutics, SCYNEXIS, Inc.

**Report ID:** MRFR/HC/30154-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Virendra Rathod · **Last Updated:** November 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/anti-fungal-drugs-market-31940

---

## Market Summary

## Anti-Fungal Drugs Market Summary

The global anti-fungal drugs market was valued at USD 18.30 billion in 2025 and is projected to reach USD 19.01 billion in 2026, climbing to USD 27.41 billion by 2035 at a CAGR of 4.15% over 2026–2035. Two catalysts anchor that trajectory. The World Health Organization's first Fungal Priority Pathogens List placed Candida auris, Aspergillus fumigatus and Cryptococcus neoformans in its critical tier, redirecting public research budgets toward fungal disease [1]. In the United States, the Generating Antibiotic Incentives Now (GAIN) Act continues to grant five years of added exclusivity and priority review to qualified antifungal candidates, improving the commercial case for new molecules.

Therapy is shifting from daily-dosed, fungistatic azole regimens toward long-acting and mechanistically new agents. Once-weekly rezafungin, the first-in-class triterpenoid ibrexafungerp and pipeline assets such as olorofim and fosmanogepix are displacing the assumption that hospitalised patients need daily infusions or that resistant infections leave clinicians with amphotericin B as the only fallback[7][14]. Global incidence estimates of 6.5 million invasive fungal infections and 3.8 million related deaths each year give payers a hard number to weigh against premium pricing [5].

North America holds 38.4% of global revenue, supported by high transplant and oncology volumes. Asia-Pacific is the fastest-growing region at a 5.4% CAGR, while Europe ranks second at USD 5.05 billion on the strength of hospital procurement and centralised approvals. Over the decade, expect the competitive centre of gravity in the anti-fungal drugs market to move toward resistance-proof mechanisms.

## Key Report Takeaways

### • By Drug Class

- Azoles command a 56.5% share of the anti fungal drugs market in 2025, driven by low-cost generic fluconazole and voriconazole
- Echinocandins are the fastest-growing class at a 5.1% CAGR as once-weekly dosing supports outpatient infusion programs

### • By Indication

- Candidiasis leads with a 42.1% share of indication revenue, reflecting its prevalence in intensive care and oncology wards
- Onychomycosis expands at a 4.9% CAGR, fueled by ageing populations and rising diabetes prevalence

### • By Dosage Form

- Capsules account for 51.5% of sales, the default format for chronic systemic courses
- Topical Ointments/Creams grow at a 4.6% CAGR on the back of nanoparticle-enhanced penetration

### • By Distribution Channel

- Hospital Pharmacies retain a 46.0% share, tied to parenteral handling of invasive mycoses
- Online Pharmacies post the anti-fungal drugs market's highest channel growth at a 6.4% CAGR

### • By Region

- North America holds a 38.4% share of global revenue
- Asia-Pacific grows fastest at a 5.4% CAGR, led by India and China
- Europe generates USD 5.05 billion, anchored by Germany and the United Kingdom

## Market Size and Forecast (2026–2035)

Market Research Future built this anti-fungal drugs market forecast bottom-up from prescription and hospital procurement volumes across 25 countries, then validated it top-down against company-reported antifungal revenues, national health expenditure data and epidemiological incidence estimates. Historical years rest on reported sales and audited channel data; forecast years apply scenario-weighted assumptions on generic erosion, pipeline approvals and resistance trends. The 2021 jump reflects pandemic-era demand from COVID-associated [mucormycosis](https://www.marketresearchfuture.com/reports/mucormycosis-market-5440) and pulmonary aspergillosis, after which growth normalized before accelerating again from 2028 as new mechanisms reach commercial scale.

## Market Drivers

## Driver Impact Analysis

The impact percentages below are directional estimates of each driver's contribution to anti fungal drugs market growth. They overlap and interact, so they should not be added together to reproduce the headline CAGR.

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Growing immunocompromised population | +1.1% | Global, strongest in North America and Europe | Long-term (≥4 yr) | [6] |
| Spread of drug-resistant Candida auris | +0.8% | North America, Europe, MEA | Medium-term (2–4 yr) | [2] |
| Long-acting and novel-mechanism approvals | +0.7% | North America, Europe | Medium-term (2–4 yr) |   |
| Rising diabetes prevalence | +0.6% | Asia-Pacific, MEA | Long-term (≥4 yr) |   |
| Regulatory incentives for antifungal R&D | +0.5% | United States, European Union | Long-term (≥4 yr) |   |
| Climate-driven range expansion of pathogens | +0.4% | Global | Long-term (≥4 yr) | [12] |
| Digital pharmacy and teledermatology access | +0.4% | Asia-Pacific, North America | Short-term (≤2 yr) | [17] |

### Growing Immunocompromised Population

Biologic immunosuppressants, solid organ transplants, and cancer treatment continue to increase the number of individuals at risk for invasive mycoses. Another source estimates that there will be 35 million new instances of cancer by 2050, up from roughly 20 million in 2022 [6]. In 2024, the number of transplants performed in the US exceeded 48,000 [16]. Posaconazole, isavuconazole, and echinocandins are in high demand due to the fact that each of these patients usually receives antifungal prophylaxis or empirical therapy.

### Spread of Drug-Resistant Candida auris

In 2021 alone, the number of clinical cases of Candida auris in the US increased by 95%, and almost 90% of isolates are resistant to fluconazole [2]. In response, hospitals switch from fluconazole to echinocandins, which are several times more expensive each course, as the first-line treatment for candidemia. Procurement committees in the anti-fungal medicine market are pushed toward premium agents with proven action against multidrug-resistant strains due to outbreaks reported in more than 40 countries, which keeps infection-control budgets high.

### Long-Acting and Novel-Mechanism Approvals

The FDA's March 2023 approval of once-weekly rezafungin for candidemia showed that a reformulated echinocandin could earn a place on formularies by shortening hospital stays. The European Commission followed in December 2023 [13]. Pipeline candidates with new targets, including olorofim and fosmanogepix, extend this pattern to mould infections, and each approval adds a premium-priced product to a category dominated by generics.

### Rising Diabetes Prevalence

The International Diabetes Federation estimates 537 million adults lived with diabetes in 2021, a figure expected to reach 783 million by 2045. Diabetic patients face higher rates of onychomycosis, vulvovaginal candidiasis and mucormycosis. India and China account for the largest absolute numbers, which explains why Asia-Pacific shows outsized growth in both systemic and topical antifungal volumes.

### Regulatory Incentives for Antifungal R&D

The GAIN Act grants Qualified Infectious Disease Product designation, adding five years of market exclusivity and priority review. Most late-stage antifungal candidates now carry the designation. In Europe, the EMA's PRIME scheme and the proposed transferable exclusivity voucher under the pharmaceutical package reform aim to raise expected returns for antimicrobials, nudging mid-sized developers to keep fungal programs funded.

### Climate-Driven Range Expansion of Pathogens

Research published in peer-reviewed journals links rising temperatures to the thermal adaptation of Candida auris and the northward spread of Coccidioides, with valley fever cases in California exceeding 9,000 in 2023 [12]. Endemic mycoses are appearing in regions with little diagnostic familiarity. This widens the geographic footprint of demand and pushes public health agencies to strengthen fungal pathogen surveillance.

### Digital Pharmacy and Teledermatology Access

Teledermatology platforms now diagnose tinea and nail infections from photographs, and online pharmacies fulfil the resulting prescriptions within days. India's e-pharmacy segment processed an estimated 15% of urban chronic-care orders in 2024 [17]. Lower friction converts previously untreated superficial infections into paid prescriptions, adding volume to topical and oral terbinafine and itraconazole lines.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Generic price erosion on azoles | −0.9% | Global | Short-term (≤2 yr) |   |
| Antifungal resistance limiting drug utility | −0.6% | Global | Long-term (≥4 yr) | [1] |
| Hepatotoxicity and drug–drug interactions | −0.4% | Global | Medium-term (2–4 yr) |   |
| API manufacturing concentration and supply disruption | −0.4% | Global | Short-term (≤2 yr) | [8] |
| Weak diagnostic capacity in low-income settings | −0.5% | Asia-Pacific, MEA, South America | Long-term (≥4 yr) | [5] |

### Generic Price Erosion on Azoles

When the patents on fluconazole, itraconazole, voriconazole, and posaconazole expire, the greatest class of drugs is priced like a commodity. In the US, generic posaconazole tablets were introduced at 60–80% off the brand. The market for antifungal medications is growing in volume, but revenue per course is declining, which stifles value growth in the sector that still makes up more than half of category sales.

### Antifungal Resistance Limiting Drug Utility

WHO has observed that there are only four classes of systemic antifungals, and resistance is developing in all of them [1]. In certain regions of the Netherlands, the prevalence of azole-resistant Aspergillus fumigatus has reached double digits, which is associated with the use of agricultural fungicides. Rather than expanding prescribing, prescribing alters when a drug fails, and some patients pass away before an effective agent is discovered.

### Hepatotoxicity and Drug–Drug Interactions

Azoles inhibit CYP3A4, complicating co-administration with chemotherapy, immunosuppressants and antiretrovirals. FDA labelling for oral ketoconazole carries a boxed warning for liver injury and restricts use to cases with no alternative. Clinicians therefore under-prescribe or shorten courses, particularly in elderly patients with polypharmacy, trimming treatment volumes.

### API Manufacturing Concentration and Supply Disruption

A large share of antifungal active ingredients is produced in India and China, leaving supply exposed to plant inspections and export controls. The September 2023 recall of ibrexafungerp over potential cross-contamination at a third-party facility removed the product from US shelves for an extended period [8]. Hospitals now dual-source where possible, raising procurement costs.

### Weak Diagnostic Capacity in Low-Income Settings

Many hospitals in Africa and South Asia lack access to fungal culture, antigen tests or PCR. Global burden analyses estimate that a large majority of invasive fungal infections go undiagnosed in these settings [5]. Without diagnosis, treatment never starts, so a significant share of clinical need never converts into drug demand.

## Opportunities

## Anti-Fungal Drugs Market Opportunities

### Emerging-Market Access Through Tiered Pricing

India, Indonesia, Nigeria and Brazil carry heavy fungal disease burdens but low per-capita antifungal spending. Manufacturers that pair tiered pricing with WHO Essential Medicines List inclusion can convert latent need into volume, as liposomal amphotericin B access programs for cryptococcal meningitis have shown in sub-Saharan Africa [5]. Asia-Pacific's 5.4% CAGR indicates where this effort pays back first.

### Diagnostic–Therapeutic Bundles

Pairing rapid antigen or PCR tests with matched therapy creates a business model in which diagnostic data drive prescribing. Developers that partner with assay makers can embed their agents into hospital algorithms and capture real-world outcome data, which pharmacy benefit managers increasingly demand before upgrading formulary tiers.

### Outpatient Parenteral Antifungal Therapy

Once-weekly echinocandins allow patients to finish invasive candidiasis treatment at home or in infusion centres. Health systems save on bed-days, and manufacturers gain a defensible value story for premium pricing. Specialty pharmacies and home-infusion operators represent a new channel partner set for this format.

### Topical Reformulation for Nail and Skin Infections

Nanoparticle creams, microneedle patches and penetration-enhanced nail lacquers can shorten onychomycosis courses that currently last 6 to 12 months. Shorter regimens improve adherence and support pricing above generic terbinafine, particularly in Japan and the United States, where out-of-pocket willingness to pay is high.

### Real-World Data and Adherence Platforms

Adherence-tracking apps and electronic prescribing data create a monetisable data layer. Companies that aggregate anonymised treatment-outcome data can support payer negotiations, label expansions and pharmacovigilance, turning a cost centre into a commercial asset.

## Future Outlook

## Anti-Fungal Drugs Market Future Outlook

### AI-Accelerated Drug Discovery

Machine-learning screening is shortening hit-to-lead timelines for antifungal targets that historically yielded few candidates because fungal and human cells share much of their biology. Expect at least one AI-assisted antifungal candidate to enter human trials before 2030. Faster discovery matters because only a handful of new systemic classes have emerged in four decades [1].

### One Health and Agricultural Azole Policy

Agricultural azole fungicides drive resistance in Aspergillus fumigatus, linking crop protection to hospital outcomes. The EU's One Health action plan against antimicrobial resistance targets coordinated surveillance across human, animal and environmental sectors [18]. Restrictions on dual-use azoles could preserve clinical efficacy of the existing drug class and shape demand for novel agents.

### Pull Incentives and Subscription Payment

Legislative proposals such as the US PASTEUR Act would pay developers fixed annual amounts for access to critical antimicrobials, decoupling revenue from volume [19]. The UK's subscription model already pays up to GBP 20 million per year per qualifying product. If such models extend to antifungals, stewardship and commercial viability stop pulling in opposite directions.

### Decentralised and Home-Based Care

Long-acting injectables, digital adherence tools and teledermatology are moving antifungal treatment out of hospitals. US health systems that expanded hospital-at-home programs after 2020 have shown that infusion therapies can be delivered safely outside inpatient wards. Over the next decade, the share of anti fungal drugs market value captured outside hospital pharmacies should rise steadily.

## Segment Insights

## Anti-Fungal Drugs Market Segmentation

### By Drug Class

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Azoles | 56.5% share | Broad-spectrum, low-cost first-line therapy |
| Echinocandins | 5.1% CAGR | Once-weekly dosing and activity against resistant Candida |
| Polyenes | USD 1.94 Billion | Salvage therapy and cryptococcal meningitis |
| Allylamines | 11.2% share | Dermatophyte and nail infections |
| Antimetabolites | 2.1% CAGR | Combination therapy for cryptococcosis |

Within the anti fungal drugs market, Azoles lead because generic fluconazole, voriconazole and posaconazole cover most first-line regimens at low cost. Echinocandins grow fastest as rezafungin's weekly dosing supports outpatient care and resistant Candida pushes guidelines toward the class. Polyenes, chiefly liposomal amphotericin B, anchor salvage regimens. Allylamines face terbinafine-resistant dermatophytes, while Antimetabolites such as flucytosine stay confined to combination therapy.

### By Indication

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Candidiasis | 42.1% share | ICU, oncology and invasive-care prevalence |
| Dermatophytosis | USD 4.10 Billion | Tropical climates and recurrent tinea |
| Aspergillosis | 14.8% share | Haematological malignancy and transplant |
| Onychomycosis | 4.9% CAGR | Ageing populations and diabetes |
| Other Systemic & Opportunistic Mycoses | USD 1.43 Billion | Cryptococcosis, mucormycosis, endemic mycoses |

Candidiasis is the largest indication in the anti fungal drugs market, reflecting its frequency in catheterised and immunosuppressed patients and the high cost of treating resistant Candida auris. Onychomycosis grows fastest, supported by older and diabetic populations and willingness to pay for shorter regimens. Dermatophytosis generates steady volume across South Asia, Aspergillosis drives mould-active azole use, and Other Systemic & Opportunistic Mycoses include cryptococcosis and mucormycosis.

### By Dosage Form

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Capsules | 51.5% share | Chronic systemic oral courses |
| Topical Ointments/Creams | 4.6% CAGR | Nanoparticle penetration and adherence |
| Parenteral Injectables | USD 4.65 Billion | Critical-care treatment of invasive infections |
| Powders & Sprays | 6.2% share | Sports-related and intertriginous infections |

Across the anti fungal drugs market, Capsules dominate because oral itraconazole, fluconazole and terbinafine suit long systemic courses. Topical Ointments/Creams grow fastest as nanoparticle-enhanced formulations penetrate deeper and shorten application periods. Parenteral Injectables remain essential in intensive care, with long-acting rezafungin opening home-infusion options. Powders & Sprays serve athletes and humid-climate consumers through retail channels, often combined with mild corticosteroids for inflamed skin.

### By Distribution Channel

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 46.0% share | Parenteral handling and stewardship oversight |
| Retail Pharmacies | USD 7.85 Billion | OTC dermatology and refilled oral prescriptions |
| Online Pharmacies | 6.4% CAGR | Teleconsultation and home delivery |

For the anti fungal drugs market, Hospital Pharmacies lead because invasive mycoses require parenteral drugs dispensed under antifungal stewardship protocols. Online Pharmacies grow fastest as teleconsultations and doorstep delivery convert untreated skin and nail infections into prescriptions. Retail Pharmacies stay central for over-the-counter creams and powders, particularly in Southeast Asia and Latin America, where pharmacy counters often serve as the first point of care.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.4% share | Premium novel agents, outpatient infusion, C. auris control |
| Europe | USD 5.05 Billion | Centralised approvals, hospital stewardship, generic tenders |
| Asia-Pacific | 5.4% CAGR | Diabetes-linked demand, e-pharmacy growth, local generics |
| South America | 5.6% share | Endemic mycoses, public procurement |
| Middle East & Africa | USD 0.97 Billion | Cryptococcal meningitis access, GCC hospital build-out |
| Total | USD 18.30 Billion | — |

Regional dynamics in the anti fungal drugs market follow healthcare spending, transplant and oncology volumes, and the burden of diabetes and tropical skin infections. North America leads on value, while Asia-Pacific supplies the fastest growth.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 86.5% share of region | Transplant volumes and C. auris outbreaks |
| Canada | USD 0.62 Billion | Provincial formulary listings for newer azoles |
| Mexico | 4.9% CAGR | Diabetes burden and expanding private pharmacy chains |

The United States sets global pricing benchmarks and absorbs most launches of new agents. The CDC's tracking of more than 4,500 clinical C. auris cases in 2023 keeps hospital spending on echinocandins elevated [2]. Canada's market follows provincial formulary decisions, which tend to lag US uptake by 12 to 24 months. Mexico's growth reflects one of the world's highest diabetes prevalence rates and a fast-growing [retail pharmacy](https://www.marketresearchfuture.com/reports/retail-pharmacy-market-22432) network that supplies most topical products without prescription.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 23.8% share of region | Large hospital sector and haemato-oncology centres |
| United Kingdom | USD 0.86 Billion | NHS stewardship programs and antifungal subscription pilots |
| France | 3.6% CAGR | Hospital tender pricing and transplant activity |
| Italy | 12.4% share of region | Ageing population and onychomycosis prevalence |
| Spain | USD 0.49 Billion | Regional procurement and ICU capacity |
| Rest of Europe | 24.1% share of region | Azole-resistant Aspergillus in the Netherlands and Nordics |

Europe combines high diagnostic capacity with aggressive generic tendering. The European Commission's December 2023 authorisation of rezafungin created a second major market for long-acting echinocandins [13]. Germany's density of haemato-oncology centres sustains mould-active azole demand, while the United Kingdom's NHS has tested subscription-style payment for antimicrobials, a model that could extend to antifungals. Resistance pressure from agricultural azoles keeps surveillance budgets active across the region.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 34.6% share of region | Hospital expansion and volume-based procurement |
| Japan | USD 1.02 Billion | Elderly population and premium onychomycosis therapy |
| India | 7.1% CAGR | Diabetes burden, mucormycosis legacy, e-pharmacy |
| Australia | 6.8% share of region | Transplant programs and PBS listings |
| South Korea | USD 0.31 Billion | Oncology volumes and national reimbursement |
| Rest of Asia-Pacific | 5.8% CAGR | Tropical dermatophytosis in Southeast Asia |

Asia-Pacific's growth rests on demographics and access. India's 2021 mucormycosis wave, which exceeded 47,000 reported cases, forced lasting investment in liposomal amphotericin B supply [11]. China's volume-based procurement compresses azole prices but widens access. Japan stands apart as a high-value market where newer topical agents for nail infections command premium prices, and Southeast Asia's humid climate keeps dermatophytosis demand high.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.2% share of region | SUS procurement and endemic paracoccidioidomycosis |
| Argentina | USD 0.17 Billion | Hospital infection-control programs |
| Rest of South America | 4.3% CAGR | Expanding retail pharmacy access |

Brazil dominates regional demand through its public health system, which buys antifungals centrally for HIV-associated [cryptococcosis](https://www.marketresearchfuture.com/reports/cryptococcosis-market-9254) and endemic mycoses such as paracoccidioidomycosis and histoplasmosis. Argentina's hospitals have reported C. auris clusters, prompting new infection-control protocols. Across Colombia, Peru and Chile, growth in pharmacy chains expands over-the-counter topical sales, although currency volatility limits uptake of imported branded products.

### Middle East & Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 41.5% share of region | Hospital build-out and specialist care investment |
| South Africa | 4.8% CAGR | HIV-associated cryptococcal meningitis |
| Rest of Middle East & Africa | USD 0.29 Billion | Donor-funded access programs |

GCC states are investing heavily in tertiary hospitals and transplant centres, raising demand for branded systemic agents. South Africa carries a heavy cryptococcal meningitis burden tied to HIV, and single high-dose liposomal amphotericin B regimens recommended by WHO are widening treatment access [5]. Elsewhere in Africa, donor programs and the Global Action for Fungal Infections network remain the main routes to supply.

## Competitive Benchmarking

## Competitive Benchmarking

Competition in the anti fungal drugs market is moderately fragmented. Market Research Future estimates a Herfindahl-Hirschman Index of roughly 850–1,050 and a combined top-five share of about 40–45%. Global majors lean on manufacturing scale and regulatory experience, generic producers dominate azole volumes, and biotech firms compete on new mechanisms and long-acting formulations. Patent expiries on major azoles favour cost leaders, while exclusivity on newer agents such as oteseconazole and rezafungin protects premium niches.

| Company | Est. Revenue Share Range | Key Offerings for anti fungal drugs market | Strategic Positioning |
| --- | --- | --- | --- |
| Pfizer Inc. | ~10–13% | Vfend (voriconazole), Eraxis (anidulafungin), Diflucan | Broad hospital portfolio with global reach |
| Merck & Co., Inc. | ~8–11% | Noxafil (posaconazole), Cancidas (caspofungin) | Mould-active azole leadership in oncology |
| Astellas Pharma Inc. | ~6–9% | Cresemba (isavuconazole), Mycamine (micafungin) | Hospital-focused invasive infection franchise |
| Gilead Sciences, Inc. | ~5–8% | AmBisome (liposomal amphotericin B) | Salvage and cryptococcal therapy, access programs |
| Basilea Pharmaceutica | ~3–5% | Cresemba partnership, fosmanogepix pipeline | Specialist anti-infective developer |
| Melinta Therapeutics | ~1–3% | Rezzayo (rezafungin) US rights | Long-acting echinocandin commercialisation |
| Cidara Therapeutics | ~1–2% | Rezafungin originator, Rezafungin royalties | Platform innovation and licensing |
| SCYNEXIS, Inc. | ~1–2% | Brexafemme (ibrexafungerp) | First-in-class triterpenoid via GSK partnership |
| GSK plc | ~1–3% | Ibrexafungerp licensed rights | Big-pharma marketing reach for novel agents |
| Mycovia Pharmaceuticals | ~1–2% | Vivjoa (oteseconazole) | Recurrent vulvovaginal candidiasis niche |
| Bayer AG | ~3–5% | Canesten (clotrimazole) consumer range | OTC topical brand leadership |
| Glenmark Pharmaceuticals | ~2–4% | Generic azoles, terbinafine, topical combinations | Cost-led emerging-market supplier |

## Recent News & Developments

## Recent News & Developments

- FDA (March 2023): Approved Melinta and Cidara's Rezzayo (rezafungin) for candidemia and invasive candidiasis, the first new candidemia therapy in over a decade and the first once-weekly echinocandin
- GSK and SCYNEXIS (March 2023): Signed an exclusive licence for Brexafemme (ibrexafungerp), combining a first-in-class oral agent with a global commercial organisation [7]
- F2G (June 2023): Received an FDA complete response letter for olorofim, requiring further data and delaying the first orotomide's entry into the mould infection market [14]
- SCYNEXIS (September 2023): Recalled Brexafemme over potential cross-contamination at a supplier, highlighting manufacturing concentration risk [8]
- Basilea Pharmaceutica (November 2023): Acquired fosmanogepix, a first-in-class Gwt1 inhibitor, adding a broad-spectrum candidate to its antifungal portfolio [20]
- European Commission (December 2023): Granted marketing authorisation for rezafungin in adults with invasive candidiasis [13]
- CDC (March 2024): Reported continued growth in clinical Candida auris cases across US states, reinforcing hospital investment in screening and echinocandin therapy [2]
- WHO (April 2025): Published its first reports on antifungal diagnostics and treatments, flagging critical gaps in the pipeline [21]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The anti fungal drugs market covers prescription and over-the-counter antifungal medicines across azole, echinocandin, polyene, allylamine and antimetabolite classes, sold through hospital, retail and online pharmacies for superficial and systemic fungal infections. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 18.30 Billion |
| Market Size in 2035 | USD 27.41 Billion |
| CAGR (2026–2035) | 4.15% |
| Fastest Growing Segments | Online Pharmacies (6.4% CAGR); Echinocandins (5.1% CAGR); Onychomycosis (4.9% CAGR); Topical Ointments/Creams (4.6% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Pfizer Inc., Merck & Co. Inc., Astellas Pharma Inc., Gilead Sciences Inc., Basilea Pharmaceutica, Melinta Therapeutics, Cidara Therapeutics, SCYNEXIS Inc., GSK plc, Mycovia Pharmaceuticals, Bayer AG, Glenmark Pharmaceuticals |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: Which pipeline mechanisms could reshape the anti fungal drugs market after 2028?**
A: Orotomides such as olorofim and Gwt1 inhibitors such as fosmanogepix target pathways no approved drug uses [14][20]. Their activity against azole-resistant moulds positions them in the anti fungal drugs market as premium salvage options once approved.

**Q: How do hospital buyers justify premium echinocandins over generic azoles?**
A: Pharmacy committees weigh drug cost against bed-day savings and resistance risk. A once-weekly echinocandin that enables early discharge can offset a higher acquisition price within one admission [3].

**Q: What regulatory risk should investors in the anti fungal drugs market watch most closely?**
A: Manufacturing compliance carries outsized risk for small anti fungal drugs market developers with single-source supply. The Brexafemme recall showed how one supplier issue can halt sales of an entire product line [8].

**Q: Are antifungal subscription payment models likely to spread?**
A: The UK model already pays fixed annual fees for qualifying antimicrobials. If the PASTEUR Act passes, US developers would gain a comparable revenue floor less tied to prescription volume [19].

**Q: How does agricultural fungicide policy affect the anti fungal drugs market?**
A: Agricultural azoles select for resistant Aspergillus fumigatus in the environment. Tighter crop-protection rules could slow resistance across the anti fungal drugs market and extend the useful life of clinical azoles [18].

**Q: Which emerging use case could open a new prescribing niche?**
A: Fungal keratitis, a leading cause of corneal blindness in tropical regions, lacks approved targeted eye-drop therapy. Nanomicelle ophthalmic formulations in development could create a dedicated specialty segment [5].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/anti-fungal-drugs-market-31940*
